Experience of professor Li Peiwen in treating cardiotoxicity related to breast cancer treatment
ZHOU Jialin1 WANG Zhaodongfang1 ZHANG Jing1 WAN Donggui2
1.China-Japan Friendship Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Oncology Department of Integrated Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing 100029, China
Abstract:Anthracycline chemotherapy drugs and targeted drugs such as Trastuzumab are commonly used anti-tumor drugs in the treatment of breast cancer, and cardiotoxicity is the common reason to limit their use, which seriously affects the anti-cancer treatment and prognosis of breast cancer patients. With the gradual development of breast conserving surgery, left chest wall radiotherapy induced cardiac injury is also one of the influencing factors of breast cancer patients with cardiac dysfunction in the future. Professor Li Peiwen has rich clinical experience in the diagnosis and treatment of cardiotoxicity related to breast cancer treatment. He thinks that the treatment of cardiotoxicity caused by anthracycline drugs, Trastuzumab and radiotherapy are different. Cardiotoxicity caused by Trastuzumab is mainly deficiency of heart qi, cardiotoxicity caused by anthracyclines is mainly blood stasis, and cardiotoxicity caused by left chest wall radiotherapy is mainly yin deficiency. In the treatment, the methods of benefiting heart qi, promoting blood circulation and removing blood stasis, eliminating heat by nourishing yin have achieved satisfactory clinical results.
周佳琳1 王照东方1 张静1 万冬桂2. 李佩文教授辨治乳腺癌治疗相关心脏毒性经验[J]. 中国医药导报, 2020, 17(34): 146-149.
ZHOU Jialin1 WANG Zhaodongfang1 ZHANG Jing1 WAN Donggui2. Experience of professor Li Peiwen in treating cardiotoxicity related to breast cancer treatment. 中国医药导报, 2020, 17(34): 146-149.
[1] 陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床,2015,42(13):668-674.
[2] Patnaik JL,Byers T,Diguiseppi C,et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer:a retrospective cohort study [J]. Breast Cancer Res,2011,13(3):R64.
[3] 李田宏,谢晓冬.抗肿瘤药物心脏毒性的中医药防治进展[J].中国肿瘤临床与康复,2019,26(4):510-512.
[4] 桑震池,徐三彬,钱俊峰,等.黄芪总皂苷对心力衰竭大鼠心功能及左室重构的影响[J].中西医结合心脑血管病杂志,2017,15(17):2114-2116.
[5] 朱慧.人参治疗慢性心力衰竭临床观察[J].光明中医,2019,34(8):1208-1210.
[6] 刘甜甜,姚魁武,段锦龙.血府逐瘀汤治疗心血管病的药理机制研究进展[J].吉林中医药,2019,39(10):1397-1400.
[7] 林炜基,李绍烁,韩敬端,等.血府逐瘀汤加减治疗慢性心力衰竭的Meta分析[J].现代中药研究与实践,2018, 32(6):65-69.
[8] 郭建红,郑宗兵.血府逐瘀汤用于气滞血瘀心悸的临床疗效观察[J].临床医学工程,2019,26(8):1089-1090.
[9] 马莹慧,王艺璇,刘雪,等.丹参药理活性研究进展[J].吉林医药学院学报,2019,40(6):440-442.
[10] 董帅,王辉,谢治深.丹参功用本草考证及现代药理认识[J].辽宁中医药大学学报,2019,21(11):152-155.
[11] 李海文,杨志明,高福萍,等.丹参多酚对阿霉素心脏毒性损伤保护机制的研究[J].毒理学杂志,2019,33(4):293-297.
[12] 董庆海,吴福林,王涵,等.延胡索药学研究进展[J].中国野生植物资源,2019,38(1):48-53,79.
[13] 尚坤,李敬文,常美月,等.延胡索药理作用研究[J].吉林中医药,2019,39(1):108-110.
[14] 吕运权,张恒.川芎和郁金防治冠心病的研究进展[J].中西医结合心脑血管病杂志,2019,17(7):1011-1013.
[15] 罗仁书,何治勇.川芎有效成分药理作用的研究进展[J].中国医院用药评价与分析,2018,18(9):1294-1296.
[16] 曹占鸿,潘建衡,李娜,等.生脉散现代药理作用及作用机制的研究进展[J].中国实验方剂学杂志,2019,25(22):212-218.
[17] 赵振彪,王辉,刘歌,等.麦冬药性与功用考证[J].中医药导报,2019,25(5):82-85.
[18] 孙晓媛,于凡,肖伟,等.麦冬现代应用的研究进展[J].中国现代中药,2018,20(11):1453-1458.
[19] 李庆敏,瞿武林,陈伯钧.铁皮石斛对缺血再灌注后心衰心气虚型大鼠心肌纤维化的抑制作用[J].中国实验方剂学杂志,2019,25(15):83-88.
[20] 陈广文,赵林.抗肿瘤药物相关心功能不全的预防与治疗[J].中国医学科学院学报,2019,41(6):842-850.
[21] 陈浩然,孔令泉,吴凯南.乳腺癌靶向治疗相关心脏毒性防治的研究进展[J].中国临床新医学,2019,12(4):361-365.